AGF Management Ltd. Has $6.93 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

AGF Management Ltd. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 93.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,260 shares of the medical research company’s stock after selling 540,325 shares during the quarter. AGF Management Ltd.’s holdings in IQVIA were worth $6,929,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of IQV. Inspire Advisors LLC grew its position in shares of IQVIA by 10.1% in the fourth quarter. Inspire Advisors LLC now owns 2,584 shares of the medical research company’s stock valued at $508,000 after purchasing an additional 236 shares during the last quarter. Citizens Financial Group Inc. RI grew its position in shares of IQVIA by 14.5% in the fourth quarter. Citizens Financial Group Inc. RI now owns 2,820 shares of the medical research company’s stock valued at $554,000 after purchasing an additional 357 shares during the last quarter. Independent Advisor Alliance grew its position in shares of IQVIA by 49.7% in the fourth quarter. Independent Advisor Alliance now owns 1,729 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 574 shares during the last quarter. Meriwether Wealth & Planning LLC acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $505,000. Finally, Daiwa Securities Group Inc. grew its position in shares of IQVIA by 17.7% in the fourth quarter. Daiwa Securities Group Inc. now owns 44,302 shares of the medical research company’s stock valued at $8,706,000 after purchasing an additional 6,651 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on IQV. Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Barclays cut their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Up 1.1 %

Shares of NYSE:IQV opened at $185.47 on Thursday. The company has a fifty day moving average of $197.14 and a 200-day moving average of $211.59. The company has a market capitalization of $32.70 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.72.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.